Australia's largest stock trading and investment forum Australia's #1 stock forum

BOT

0.00%

33.5¢ botanix pharmaceuticals ltd

Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-863

First 863 Last

Share
Profile

Follow
bernsta

4,383 Posts.

1313

10/02/21

22:55

Post #: 50878002
Share

Originally posted by bigfella195: ↑

When the 1801 results were announced I was pleased that the primary endpoints had been achieved but was left with a few questions. I popped off an email to Botanix and this morning was able to get some answers. They could not have been any more open and forth coming, very appreciative. Thought I would share some insights:

- All 66 participants completed the trial. The participants were tested 3 times prior to the trial to determine if they had Staph Aureus. If they did not have a staph infection on the third test their data was not included and hence the percentages (A post yesterday clarified the calculations).

- There was no data collected at the end of day 5 as the trial was set up around the protocols of trials completed for other nasal decolonization products.

- 2 participants had MRSA, too few to be considered statistically significant. 1 in the vehicle group and 1 in the ointment group. The MRSA in the vehicle group was not eliminated, while the MRSA in the ointment group was successfully eliminated. Botanix had hoped there would be more MRSA cases.

- Side effects were really very mild, a little crustiness in some cases.

- The ASX no longer allow pharmaceutical companies to present comparisons with other company’s trials in announcements.

- The level of nasal staph was coded as eliminated, light, moderate or high. Data about staph levels in participants who were not classified as eliminated is still to come through.

- Participants who were recolognised by staph had there staph treated again and the staph was, in all cases, still susceptible suggesting no resistance development.

- In terms of recolognisation, staph is carried on many parts of the body and persistent carriers recolognize a lot. Other nasal decolonization studies gave participants full body chlorhexadine washes prior to the trial, something that was not done in Botanix’s trial.

- More data about the 1801 trial is still to come in.

-Matt Callaghan will be presenting remotely at a conference next week and hopefully will provide more data about the trial.

It is clear to me that Botanix genuinely believe the data is very good and compares well to competitors in the staph decolonization space, dialysis is one area they think this has some real potential.

My doubts about the results, based on some basic Google searches of other trials, were completely allayed. IMO Botanix is on to something and I’m not selling any time soon. Look forward to Matt’s presentation next week.

Expand

Great post again mate.

Be nice if this was further communicated in the announcements. Shareholder are left wanting more clarification. We are just battlers having a go.

BOT Price at posting: 15.0¢ Sentiment: Buy Disclosure: Held
13 Upvote

1 Great analysis

Reply

Top Stories

Your questions From the Floor: Investment experts respond...

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

BRX

Belararox delineates another porphyry in Argentina at Tambo South

GYG

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

TM1

Shares up 196% on Terra's news of major reef discovery at Dante

There are more pages in this discussion • 138 more messages in this thread...

First 863 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 33.5¢		Change 0.000(0.00%)		Mkt cap ! $527.6M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	32083	48.0¢

Sellers (Offers)

Price($)	Vol.	No.
32.0¢	50000	3

View Market Depth

No.	Vol.	Price($)
2	32083	0.480
2	44404	0.470
1	2000	0.460
8	38807	0.450
1	20000	0.430

Price($)	Vol.	No.
0.320	20000	2
0.330	50000	1
0.335	10019	2
0.345	2874	1
0.350	635431	12

Last trade - 16.16pm 20/06/2024 (20 minute delay)

BOT (ASX) Chart

Day chart unavailable

Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-863

Your questions From the Floor: Investment experts respond...

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Belararox delineates another porphyry in Argentina at Tambo South

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Shares up 196% on Terra's news of major reef discovery at Dante

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-863

Top Stories

Your questions From the Floor: Investment experts respond...

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Belararox delineates another porphyry in Argentina at Tambo South

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Shares up 196% on Terra's news of major reef discovery at Dante

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News